{"id":"NCT00995709","sponsor":"Novartis Pharmaceuticals","briefTitle":"Phase III Study in Refractory Behcet's Disease","officialTitle":"A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-10-15","resultsPosted":"2015-08-31","lastUpdate":"2015-08-31"},"enrollment":118,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Behcet Disease"],"interventions":[{"type":"DRUG","name":"AIN457","otherNames":[]},{"type":"DRUG","name":"AIN457","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AIN457C 300 mg every 2 week dosage regimen","type":"EXPERIMENTAL"},{"label":"AIN457C 300 mg monthly dosage regimen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.","primaryOutcome":{"measure":"Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"AIN457C 300 mg Every 2 Week Dosage Regimen","deltaMin":7.7,"sd":22.4},{"arm":"AIN457C 300 mg Monthly Dosage Regimen (a)","deltaMin":11.5,"sd":28.19},{"arm":"Placebo to AIN457C","deltaMin":7.7,"sd":22.35}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":49,"countries":["United States","Egypt","France","Germany","Greece","Hong Kong","India","Israel","Italy","Jordan","Singapore","South Korea","Spain","Switzerland","Taiwan","Tunisia","Turkey (Türkiye)"]},"refs":{"pmids":["23290985"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":39},"commonTop":["Headache","Pyrexia","Arthralgia","Nausea","Fatigue"]}}